MedTrace Logo

Investigate the Safety Tolerability and Pharmacokinetics of Multiple Doses of AZD1236

NCT00767052 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2009-06-30

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of multiple ascending oral doses of AZD1236 given to healthy young subjects for 13 days and to evaluate the single-dose relative bioavailability of the oral suspension and oral tablet formulations.

Conditions

  • Healthy Volunteer

Interventions

DRUG

AZD1236

75mg once daily or 75mg twice daily will be administered in multiple dose part.

DRUG

Placebo

Placebo tablet matching to the active in multiple dose part.

DRUG

AZD1236

75mg single dose will be administered in relative bioavailability part.

DRUG

AZD1236

75mg oral suspension single dose will be administered in relative bioavailability part.

Sponsors & Collaborators

Principal Investigators

  • Shunji Matsuki, MD PhD · Kyushu Clinical Pharmacology Research Clinic

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-09-30
Completion
2008-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00767052 on ClinicalTrials.gov